热门资讯> 正文
2025-11-06 21:01
Iovance Biotherapeutics (NASDAQ: IOVA) affirms FY2025 sales outlook from $250.000 million-$300.000 million to $250.000 million-$300.000 million vs $264.918 million estimate.